| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Zheng,Yu-Xiu | Chairman | 1.08% | HONG YU INVESTMENT CO., LTD. |
| Lin,Hong-Yuan | Director | 1.08% | HONG YU INVESTMENT CO., LTD. |
| Li,Hui-Qian | Director | 19.19% | LI KANG BIOTECHNICAL CO., LTD. |
| Huang,Ya-Yi | Director | 19.19% | LI KANG BIOTECHNICAL CO., LTD. |
| Xu,Rui-Xiang | Independent Director | 0.00% | |
| Huang,Shi-Ying | Independent Director | 0.00% | |
| Chen,Zhi-Lin | Independent Director | 0.00% | |
| Chen,Zhi-Chang | Independent Director | 0.00% |
Change Company Name to LI KANG BIOMEDICAL CO., LTD
2024/03/11
Change Company Name to LIKANG BIOMEDICAL CO., LTD. (FORMER NAME: HENGFENG TECHNOLOGY CO., LTD.)
2022/07/26
Change Person in Charge to Zheng,Yu-Xiu
2015/01/09
Change Company Name to LI KANG BIOMEDICAL CO., LTD
2014/09/12
Change Person in Charge to Zheng,Qing-Xiang
2014/09/12
Change Company Name to HENG FENG TECHNOLOGY CO., LTD.
2011/07/08
下載完整報告查看完整數據
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating income | 134,793 | 565,515 | 629,379 |
| Operating cost | 43,247 | 179,418 | 203,234 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 91,546 | 386,097 | 426,145 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 91,546 | 386,097 | 426,145 |
| Operating expenses | 71,994 | 296,076 | 292,774 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | 19,552 | 90,021 | 133,371 |
| Non-operating income and expenses | 2,155 | 9,167 | 5,773 |
| Net profit (loss) before tax | 21,707 | 99,188 | 139,144 |
| Income tax expense (benefits) | 4,831 | 22,164 | 28,151 |
| Net profit (loss) of ongoing business for the current period | 16,876 | 77,024 | 110,993 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | 16,876 | 77,024 | 110,993 |
| Other comprehensive profit (loss), net | -2,430 | -1,500 | -4,500 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | 14,446 | 75,524 | 106,493 |
| Net profit (loss) attributable to owners of parent company | 16,876 | 77,024 | 110,993 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | - | - | - |
| Comprehensive profit (loss) attributable to owners of parent company | 14,446 | 75,524 | 106,493 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | - | - |
| Basic earnings per share (yuan) | 0 | 2 | 4 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | 18,417 | 65,382 | 96,744 |
| Net cash inflows (outflows) from investing activities | 62,759 | -257,760 | -61,841 |
| Net cash inflow (outflow) from financing activities | 0 | 145,483 | -55,073 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | - | - | - |
| Increase (decrease) in cash and cash equivalents in the current period | 81,176 | -46,895 | -20,170 |
| Beginning balance of cash and cash equivalents | 64,947 | 111,842 | 132,012 |
| Ending balance of cash and cash equivalents | 146,123 | 64,947 | 111,842 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Current asset | 516,515 | 512,708 | 355,682 |
| Non-current asset | 572,321 | 522,904 | 471,323 |
| Total asset | 1,088,836 | 1,035,612 | 827,005 |
| Current liability | 134,630 | 94,049 | 109,689 |
| Non-current liability | 84,077 | 85,880 | 87,284 |
| Total liability | 218,707 | 179,929 | 196,973 |
| share capital | 318,065 | 318,065 | 268,065 |
| Equity - secruity token | - | - | - |
| capital reserve | 213,389 | 213,389 | 33,745 |
| retained earning | 353,433 | 336,557 | 339,050 |
| Other equity | -14,758 | -12,328 | -10,828 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | 870,129 | 855,683 | 630,032 |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | - | - |
| Total Equity | 870,129 | 855,683 | 630,032 |
| Share capital awaiting retirement (unit: share) | - | - | - |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 27 | 26 | 23 |
